An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer

Castrate-resistant Prostate Cancer (CRPC) Clinical Trial

Official title:
A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)

Status Terminated

Clinical Trial Summary

This Phase 2 Open-label Study examines the efficacy, safety, tolerability, and pharmacokinetics (PK) of tomivosertib (eFT508) in Patients with advanced CRPC. An Open-label Study Examining the Effect of tomivosertib (eFT508) in Patients with Advanced Castrate-resistant Prostate Cancer (CRPC)

Clinical Trial Description

This Phase 2 study examines the efficacy, safety, tolerability, and pharmacokinetics (PK) of tomivosertib (eFT508) in advanced CRPC patients who have documented PSA progression on treatment with apalutamide and/or abiraterone and/or enzalutamide and for whom no suitable curative therapy exists. ;

Study Design

Related Conditions & MeSH terms

Castrate-resistant Prostate Cancer (CRPC)
Prostatic Neoplasms

Clinical Trial Details

NCT number	NCT03690141
Study type	Interventional
Source	Effector Therapeutics
Contact
Status	Terminated
Phase	Phase 2
Start date	November 27, 2018
Completion date	April 27, 2020

View Details

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT01450683` - Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy	Phase 2
	Terminated	`NCT01020305` - Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer	Phase 1/Phase 2